Kazia Therapeutics Ltd (KZIA) has a current Price-to-Book (P/B) ratio of -1.46. Compared to its 3-year average P/B ratio of 0.97, the current P/B ratio is approximately -250.46% higher. Relative to its 5-year average P/B ratio of 2.41, the current P/B ratio is about -160.43% higher. Kazia Therapeutics Ltd (KZIA) has a Forward Free Cash Flow (FCF) yield of approximately -16.31%. Compared to its 3-year average FCF yield of -80.64%, the current FCF yield is approximately -79.78% lower. Relative to its 5-year average FCF yield of -61.55%, the current FCF yield is about -73.51% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for KZIA competitors is 278.01, providing a benchmark for relative valuation. Kazia Therapeutics Ltd Corp (KZIA.O) exhibits a P/S ratio of 1661.69, which is 497.71% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of KZIA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of KZIA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is KZIA currently overvalued or undervalued?

What is Kazia Therapeutics Ltd (KZIA) fair value?

KZIA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Kazia Therapeutics Ltd (KZIA) is between to according to relative valuation method.

How does KZIA's valuation metrics compare to the industry average?

The average P/S ratio for KZIA's competitors is 278.01, providing a benchmark for relative valuation. Kazia Therapeutics Ltd Corp (KZIA) exhibits a P/S ratio of 1661.69, which is 497.71% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Kazia Therapeutics Ltd (KZIA) as of Mar 02 2026?

As of Mar 02 2026, Kazia Therapeutics Ltd (KZIA) has a P/B ratio of -1.46. This indicates that the market values KZIA at -1.46 times its book value.

What is the current FCF Yield for Kazia Therapeutics Ltd (KZIA) as of Mar 02 2026?

As of Mar 02 2026, Kazia Therapeutics Ltd (KZIA) has a FCF Yield of -16.31%. This means that for every dollar of Kazia Therapeutics Ltd's market capitalization, the company generates -16.31 cents in free cash flow.

What is the current Forward P/E ratio for Kazia Therapeutics Ltd (KZIA) as of Mar 02 2026?

As of Mar 02 2026, Kazia Therapeutics Ltd (KZIA) has a Forward P/E ratio of -635.96. This means the market is willing to pay $-635.96 for every dollar of Kazia Therapeutics Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kazia Therapeutics Ltd (KZIA) as of Mar 02 2026?

As of Mar 02 2026, Kazia Therapeutics Ltd (KZIA) has a Forward P/S ratio of 1661.69. This means the market is valuing KZIA at $1661.69 for every dollar of expected revenue over the next 12 months.

KZIA Valuation